Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients
Autore:
Bernengo, MG; Quaglino, P; Cappello, N; Lisa, F; Osella-Abate, S; Fierro, MT;
Indirizzi:
Univ Turin, Dept Med & Surg Specialt, Sect Dermatol 1, I-10126 Turin, Italy Univ Turin Turin Italy I-10126 lt, Sect Dermatol 1, I-10126 Turin, Italy Univ Turin, Dept Genet Biol & Med Chem, Sect Med Stat, Turin, Italy Univ Turin Turin Italy net Biol & Med Chem, Sect Med Stat, Turin, Italy
Titolo Testata:
MELANOMA RESEARCH
fascicolo: 1, volume: 10, anno: 2000,
pagine: 55 - 65
SICI:
0960-8931(200002)10:1<55:MIMTEO>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACTIVATED KILLER-CELLS; INTERFERON-ALPHA; MALIGNANT-MELANOMA; SERUM LEVELS; CLINICAL-RESPONSE; CANCER-PATIENTS; SEQUENTIAL CHEMOIMMUNOTHERAPY; DOSE INTERLEUKIN-2; PROGNOSTIC FACTORS; IL-2 TREATMENT;
Keywords:
biological response modifiers; interleukin-2; interleukin-12; macrophage activation; metastatic melanoma therapy; multivariate analysis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
60
Recensione:
Indirizzi per estratti:
Indirizzo: Bernengo, MG Univ Turin, Dept Med & Surg Specialt, Sect Dermatol 1, Via Cherasco 23, I-10126 Turin, Italy Univ Turin Via Cherasco 23 Turin Italy I-10126 Turin, Italy
Citazione:
M.G. Bernengo et al., "Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients", MELANOMA RE, 10(1), 2000, pp. 55-65

Abstract

The biological mechanisms of chemoimmunotherapy efficacy in vivo have not been fully clarified; furthermore, few data are available to predict its efficacy on the basis of clinical and immunological pretreatment factors. In this paper, pre- and post-treatment serum levels of cytokines (interleukin [IL]-6, IL-10, IL-12 and neopterin) and soluble IL-2 receptors (sIL-2R), aswell as circulating levels of T-cell and NK subpopulations, were analysed according to clinical outcome in 66 advanced metastatic melanoma (MM) patients treated with subcutaneous IL-2 in association with interferon-alpha, cisplatin and tamoxifen. Our purpose was to correlate the immune modifications during treatment with the clinical response and to define pretreatment factors with predictive value for clinical outcome. The overall response ratewas 35%, with a median overall survival of 11.3 months. During treatment, responding patients showed a common marked increase in IL-12 (mainly released by activated macrophages), sIL-2R and neopterin serum levels, associatedwith high levels of total lymphocytes and circulating natural killer lymphocytes; progressing patients were characterized by an increase in IL-6 serum levels (directly related to the increase in tumour burden). Multivariate analysis showed that high pretreatment IL-12 levels (P = 0.05) and, to a lesser extent, lactate dehydrogenase levels in the normal range (less than orequal to 450 U/l; P = 0.061) are independent favourable prognostic factorsfor survival. Our results show that macrophage activation in an immunostimulating way either before or during treatment is associated with a better clinical response and improved survival in advanced MM patients treated withIL-2-based chemoimmunotherapy. (C) 2000 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 15:12:03